Global Pharmerging Markets 2017-2021

Global Pharmerging Markets 2017-2021

  • January 2017 •
  • 116 pages •
  • Report ID: 4647417 •
  • Format: PDF
About Pharmerging

The immense growth potential in pharmerging market has driven large multinational pharmaceutical companies to focus on these regions by pursuing organic as well as in-organic routes. To make in-roads into the new geography, the large players usually take in-organic route through strategic expansion initiatives such as acquisitions and alliances. For instance, in December 2015, AstraZeneca entered into a deal with WuXi to acquire its biologics manufacturing facilities in China to expand locally.

Technavio’s analysts forecast the global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global pharmerging market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of pharmaceutical drugs in pharmerging markets, which are further divided into Tier I, II and III.

The market is divided into the following segments based on geography:
- Tier 1
- Tier 2
- Tier 3

Technavio's report, Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- GlaxoSmithKline
- Pfizer
- Sanofi
- Novartis

Other prominent vendors
- Abbott Laboratories
- AbbVie
- Alexion Pharmaceuticals
- Allergan
- Amgen
- Aspen
- Astellas Pharma
- Baxter
- Bayer
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- CSL Behring
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Eisai
- Eli Lilly
- Endo Health Pharmaceuticals
- F. Hoffmann-La Roche
- Fresenius
- Gilead
- Grifols
- H. Lundbeck
- Hospira
- Johnson & Johnson
- Kyowa Hakko Kirin
- Mallinckrodt Pharmaceuticals
- Menarini
- Mitsubishi Tanabe Pharma
- Mylan
- Novo Nordisk
- Otsuka
- Shire
- STADA Arzneimittel
- Sun Pharmaceutical
- Takeda Pharma
- Teva Pharmaceutical Industries
- UCB
- Valeant Pharmaceuticals

Market driver
- Limitations in developed economies fuels demand in emerging economies
- For a full, detailed list, view our report

Market challenge
- Stringent price control and generic -centric usage lead to value erosion
- For a full, detailed list, view our report

Market trend
- Potential of new countries in emerging markets
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

About Thoracic Surgery

Thoracic surgery involves surgical treatment (open surgery or minimally invasive surgery) to address medical conditions involving the heart or lungs. It includes procedures such as redo heart surgery, aortic dissection for aortic surgery, minimally invasive mitral valve repair and replacement, and endovascular repair of thoracic aortic aneurysms. It is performed to treat end-stage heart failure, heart-lung transplants, and placement of ventricular-assist devices.

Technavio’s analysts forecast the global thoracic surgery market to grow at a CAGR of 10.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global thoracic surgery market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of medical devices required for thoracic surgeries.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Boston Scientific
- Medtronic
- Sorin
- St. Jude Medical
- Terumo

Other prominent vendors
- Abbott Vascular
- Abiomed
- AtriCure
- Biosensors International
- Biotronik
- BioVentrix
- C. R. Bard

Market driver
- Rise in incidence of cardiac disorders and increase in aging population
- For a full, detailed list, view our report

Market challenge
- Potential complications associated with cardiac surgery
- For a full, detailed list, view our report

Market trend
- Growing popularity of robot-assisted cardiac surgery
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



Methodology
Research methodology is based on extensive primary and secondary research. Primary research includes in-depth interviews with industry experts, vendors, resellers and customers. Secondary research includes Technavio Platform, industry publications, company reports, news articles, analyst reports, trade associations and the data published by Government agencies.
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.